Today, the U.S. Food and Drug Administration granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Hospital patients discharged to skilled nursing facilities often bring a high-dose painkiller prescription with them, suggesting more attention should be paid to opioid safety for those patients, research from the Oregon State University College of Pharmacy shows.
Young adults and adolescents who are prescribed opioids for the first time may be at a slightly greater risk of developing a substance-related problem later in life, according to a new study co-authored by Indiana University researchers.
Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
A test designed by UCLA researchers can pinpoint which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin, which had previously been sidelined over concerns the bacterium that causes the infection was becoming resistant to it.
The Royal Pharmaceutical Society is calling for all community pharmacists to be allowed to make changes to prescriptions that would reduce unnecessary delays in providing medicines to patients if the item prescribed was in short supply or out of stock.
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.
Published today, the first ever NICE guideline on the treatment of chronic pain has said that GPs should not prescribe opioids and other medicines like paracetamol to patients because they could be ‘harmful’ and cause addiction.
Vaccination against the human papilloma virus (HPV) reduces the risk of a condition that often leads to cervical cancer, according to an analysis of Danish health registry data.
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps for severe cases of COVID-19.
In an article published today in Australian Prescriber, pharmacist Michelle Liacos from Alfred Health in Melbourne, and her co-authors, look at stopping medicines when they are no longer needed to reduce the risk of medicine-related harm.
Design Space InPharmatics, an Industry Leader in Regulatory Drug Development, today announced its latest innovative offering for emerging biotech drug sponsors.